Drugs / Minocycline
Minocycline
also known as
minocycline hydrochloride · minocycline HCl · Arestin · FMX-101 · FMX103 · BPX-04 · DFD-29 · FXFM244 · +19 more
Small molecule targets BDNF, MMP9 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | MINOCIN | — | 1975-03-21 – 1987-07-27 | fda.gov ↗ |
| Approved | US (FDA) | MINOCIN | — | 1971-06-30 | fda.gov ↗ |
Trials 199 · started per year
today
US approved 1971
1
1
2
2
6
2
1
4
5
2
5
13
7
13
15
11
7
15
16
6
6
5
6
10
13
7
6
9
1
1970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 06 trials | ||||||
| Phase 0 | NCT07462702 | Jun 2026 → Jun 2027 expected | papillomatosis, confluent and reticulated | Medical University of South Carolina | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07298057 | Feb 2026 → Jun 2027 expected | diabetes mellitus, noninsulin-dependent, 2, periodontitis | Case Western Reserve University | Recruiting | No outcome recorded |
| Phase 0 | NCT02998151 | Jan 2016 → Nov 2020 | fragile X syndrome | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 0 | NCT02362529 | Feb 2015 → Apr 2019 | major depressive disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 0 | NCT00881907 | Mar 2010 → Mar 2014 | dental pulp necrosis | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT00881491 | Apr 2009 → Jan 2015 | dental pulp necrosis | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 122 trials | ||||||
| Phase 1 | NCT05605366 | Dec 2026 → Dec 2027 expected | cognitive disorder, cognitive impairment with or without cerebellar ataxia, sickle cell disease | University of Cincinnati | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06776445 | Jan 2024 → Jul 2025 | rosacea | First Affiliated Hospital of Chongqing Medical University | Completed | No outcome recorded |
| Phase 1 | NCT06997731 | May 2023 → Jan 2025 | chronic periodontitis | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 1 | NCT05630534 | Jan 2023 → Dec 2024 | intracerebral hemorrhage | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT05597462 | Sep 2022 → May 2023 | rosacea | Journey Medical Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02533232 | Aug → Dec 2022 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Pakistan Institute of Living and Learning | Unknown | No outcome recorded |
| Phase 1 | NCT05452785 | May 2022 | — | Journey Medical Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05032781 | Jun 2021 → Sep 2024 | ischemic stroke | Northwell Health | Withdrawn | No outcome recorded |
| Phase 1 | NCT04031755 | Apr 2019 → Oct 2020 | autism | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1 | NCT03291158 | Apr → Dec 2018 | — | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Withdrawn | No outcome recorded |
| Phase 1 | NCT02808052 | May 2017 → Jun 2018 | acute kidney injury, chronic kidney disease | Melinta Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02802631 | Apr 2017 → Feb 2018 | — | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03117530 | Apr 2017 → Dec 2022 | autism spectrum disorder | University of California, Los Angeles | Suspended | No outcome recorded |
| Phase 1 | NCT02201563 | Nov 2015 → May 2018 | radiation-induced disorder | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 1 | NCT02515955 | Aug 2015 → Mar 2016 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT02187211 | Jul 2015 → Nov 2018 | alcohol dependence | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT02272270 | Oct 2014 → Mar 2017 | glioma | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT01976065 | Sep 2014 → Sep 2018 | dental pulp necrosis | Kenneth Hargreaves | Completed | No outcome recorded |
| Phase 1 | NCT02250859 | Sep → Dec 2014 | acne | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02178813 | Jul 2014 → Jul 2016 | stroke disorder | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 1 | NCT01574742 | Jun 2012 → Jun 2014 | depressive disorder | Shalvata Mental Health Center | Unknown | No outcome recorded |
| Phase 1 | NCT00630942 | Feb 2003 → May 2007 | primary sclerosing cholangitis | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/219 trials | ||||||
| Phase 1/2 | NCT05474729 | Dec 2021 → Dec 2025 overdue | retinal degeneration, uveitis | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05680389 | Dec 2020 → Dec 2023 | cerebral amyloid angiopathy | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT05474950 | Jan 2019 → Jun 2024 | cystoid macular edema | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03050086 | Mar 2017 → Jun 2018 | rosacea | BioPharmX, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02770378 | Nov 2016 → Oct 2018 | glioblastoma | University of Ulm | Completed | No outcome recorded |
| Phase 1/2 | NCT02696512 | Mar 2016 → Mar 2017 | brain injury | International Brain Research Foundation | Unknown | No outcome recorded |
| Phase 1/2 | NCT02140164 | May 2014 → Nov 2015 | retinitis pigmentosa | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03040128 | Jun 2013 → Nov 2016 | intracerebral hemorrhage | University of Tennessee | Completed | No outcome recorded |
| Phase 1/2 | NCT01219673 | Mar 2013 → Jan 2014 | head and neck cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT01805895 | Feb 2013 → Dec 2016 | intracerebral hemorrhage | Augusta University | Completed | No outcome recorded |
| Phase 1/2 | NCT01580969 | Jul 2012 → Jan 2018 | glioma | University of Utah | Completed | No outcome recorded |
| Phase 1/2 | NCT01468831 | Mar 2012 → Feb 2020 | occlusion of tributary of retinal vein | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01468844 | Dec 2011 → Mar 2015 | retinal vein occlusion | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01120899 | Apr 2010 → Aug 2011 | diabetic macular edema | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01058395 | Feb 2010 → Sep 2015 | traumatic brain injury | Wayne State University | Completed | No outcome recorded |
| Phase 1/2 | NCT02113176 | Jan 2010 → Dec 2016 | acquired aneurysmal subarachnoid hemorrhage | University at Buffalo | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00630396 | May 2008 → Jan 2010 | stroke disorder | David Hess, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT00559494 | Jun 2004 → Aug 2010 | spinal cord injury | University of Calgary | Completed | No outcome recorded |
| Phase 1/2 | NCT00029874 | Sep 2001 → Aug 2003 | Huntington disease | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Phase 251 trials | ||||||
| Phase 2 | NCT05367362 | Dec 2025 → Mar 2026 | ischemic stroke | State University of New York at Buffalo | Withdrawn | No outcome recorded |
| Phase 2 | NCT01422148 | Jul 2025 → Jan 2027 expected | atrial fibrillation | Baystate Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06120140 | Feb 2024 → May 2027 expected | non-small cell lung carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06033846 | Oct 2023 → Jun 2024 | autoimmune encephalitis | Xijing Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06207760 | Aug 2023 → Apr 2024 | depressive disorder | IRCCS Centro San Giovanni di Dio Fatebenefratelli | Unknown | No outcome recorded |
| Phase 2 | NCT05861258 | May 2023 → May 2025 | Mycobacterium avium complex disease | Radboud University Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT05077813 | Dec 2021 → Feb 2022 | tuberculosis | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT04219735 | Jan 2020 → Nov 2021 | delirium | Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude | Completed | No outcome recorded |
| Phase 2 | NCT04068207 | Aug 2019 → Jan 2023 | retinitis pigmentosa | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT04876638 | Jul 2019 → Dec 2027 expected | brain aneurysm, brain ischemia, intracranial vasospasm | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03667222 | Sep 2018 → May 2019 | rosacea | BioPharmX, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT03489629 | Apr 2018 → Sep 2025 | cystic fibrosis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT03106740 | Oct 2017 → Apr 2024 | chronic pain syndrome | Marco Loggia | Completed | No outcome recorded |
| Phase 2 | NCT03340961 | Oct 2017 → Nov 2018 | rosacea | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 2 | NCT02946788 | Mar 2017 → Jun 2018 | acne | BioPharmX, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02564978 | Dec 2016 → Sep 2022 | age-related macular degeneration | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 2 | NCT02815332 | Aug 2016 → Mar 2017 | acne | BioPharmX, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02709096 | Apr → Jun 2016 | acne | BioPharmX, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02213575 | Mar 2016 → Nov 2018 | hypertensive disorder | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT02680379 | Mar 2016 → Oct 2017 | fragile X syndrome | University of Sherbrooke | Completed | No outcome recorded |
| Phase 2 | NCT02203552 | Jun 2015 → Jun 2020 | anxiety disorder, depressive disorder, female breast carcinoma | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02456948 | Jan 2015 → Aug 2020 | major depressive disorder | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2 | NCT02297412 | Nov 2014 → Jul 2016 | breast carcinoma, peripheral neuropathy | Academic and Community Cancer Research United | Completed | No outcome recorded |
| Phase 2 | NCT02133872 | Oct 2014 → Nov 2018 | hypertensive disorder | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT02055963 | May 2014 → Aug 2022 | head and neck cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT02056665 | Jan → Sep 2014 | Angelman syndrome | Puerta de Hierro University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01906008 | Nov 2013 → Feb 2019 | colorectal cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01809340 | Jun 2013 → Jul 2014 | depressive disorder | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT01539343 | Apr 2013 → Apr 2016 | infectious disease | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01793051 | Mar 2013 → Sep 2020 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01746043 | Feb 2013 → Jan 2017 | esophageal cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02928965 | Feb 2013 → May 2016 | schizophrenia | University of Manchester | Completed | No outcome recorded |
| Phase 2 | NCT01693523 | Jan 2013 → Sep 2018 | malignant pancreatic neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01636934 | Jul 2012 → Sep 2019 | lung cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01695291 | May 2012 → May 2017 | obsessive-compulsive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT01362010 | Jan 2012 → Jun 2013 | acne | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02051296 | Jan 2012 → Apr 2014 | chronic pain syndrome | VA Palo Alto Health Care System | Completed | No outcome recorded |
| Phase 2 | NCT01349192 | Apr 2011 → Jan 2015 | cystic fibrosis, methicillin-resistant staphylococcus aureus infectious disease | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 2 | NCT01283997 | Jan 2011 → Aug 2022 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01314482 | Nov 2010 → Dec 2013 | — | University of Adelaide | Unknown | No outcome recorded |
| Phase 2 | NCT01171326 | Aug 2010 → Mar 2012 | impetigo | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01173692 | Jul 2010 → Jul 2020 | oropharynx cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01134991 | Jun 2010 → Mar 2014 | rosacea | Vyne Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00473083 | Jan 2009 → Dec 2012 | exanthem | British Columbia Cancer Agency | Completed | No outcome recorded |
| Phase 2 | NCT00515255 | Jul 2007 → Apr 2008 | obsessive-compulsive disorder | Neuropharm | Terminated | No outcome recorded |
| Phase 2 | NCT00361257 | Mar 2007 → Jan 2010 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Terminated | No outcome recorded |
| Phase 2 | NCT00355576 | Jul 2006 → May 2007 | amyotrophic lateral sclerosis | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT01134627 | Feb 2006 → Apr 2011 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 2 | NCT00063193 | May 2003 → May 2005 | Parkinson disease | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT00536042 | Oct 1997 → Jun 2009 | asthma | State University of New York - Downstate Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00456677 | Jun 1996 → Oct 2007 | asthma | State University of New York - Downstate Medical Center | Completed | No outcome recorded |
| Phase 2/39 trials | ||||||
| Phase 2/3 | NCT07594314 | May 2026 → Dec 2028 expected | brain infarction, ischemic stroke, vascular occlusion disorder | Xiang Luo | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07594301 | May 2026 → Dec 2028 expected | arterial occlusion, ischemic stroke | Xiang Luo | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07237048 | Feb 2026 → Dec 2028 expected | intracerebral hemorrhage, ischemic stroke | Joyce Chen | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06255067 | Feb → May 2024 | periodontitis | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT06107725 | Nov 2023 → May 2024 | hemorrhagic stroke, ischemic stroke | Maimonides Medical Center | Terminated | No outcome recorded |
| Phase 2/3 | NCT04319575 | Dec 2018 → Apr 2020 | suppurative periapical periodontitis | Dr. D. Y. Patil Dental College & Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03320018 | Aug 2017 → Aug 2019 | ischemic stroke | Stony Brook University | Completed | No outcome recorded |
| Phase 2/3 | NCT01813240 | May 2013 → Apr 2015 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 2/3 | NCT00277355 | Apr 2006 → Oct 2008 | Huntington disease | Merit Cudkowicz | Completed | No outcome recorded |
| Phase 329 trials | ||||||
| Phase 3 | NCT07526987 | Jun 2026 → Dec 2028 expected | ischemic stroke | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07338175 | Apr 2026 → Jun 2028 expected | intracerebral hemorrhage | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07082855 | Jul 2025 → Feb 2028 expected | retinitis pigmentosa | Zhongshan Ophthalmic Center, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05296629 | Mar 2022 → Jun 2023 | rosacea | Journey Medical Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04960930 | Sep 2021 → Sep 2022 | acne | Cutia Therapeutics (Shanghai) Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT04291456 | Jan 2020 → Dec 2022 | multiple sclerosis | University of Calgary | Terminated | No outcome recorded |
| Phase 3 | NCT03276936 | Sep 2017 → Jan 2019 | rosacea | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03271021 | Jul 2017 → Sep 2018 | acne | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03142451 | Jun 2017 → Aug 2018 | rosacea | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04547764 | Jun 2017 → Dec 2018 | dental pulp disorder | King Abdulaziz University | Completed | No outcome recorded |
| Phase 3 | NCT04608500 | Jun 2017 → Jul 2018 | rosacea | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02928692 | Nov 2016 → Dec 2021 | colon carcinoma, prostate cancer, rectal carcinoma, renal carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02703363 | Aug 2016 → Dec 2018 | bipolar depression | Pakistan Institute of Living and Learning | Completed | No outcome recorded |
| Phase 3 | NCT02815267 | May 2016 → Oct 2017 | acne | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02815280 | May 2016 → Oct 2017 | acne | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01828203 | Jun 2013 → Jun 2018 | spinal cord injury | Rick Hansen Institute | Unknown | No outcome recorded |
| Phase 3 | NCT02541500 | Apr 2013 → Jan 2017 | amphetamine abuse, heroin dependence | Universiti Sains Malaysia | Unknown | No outcome recorded |
| Phase 3 | NCT01517334 | May 2012 → Sep 2014 | periodontal disorder | OraPharma | Completed | No outcome recorded |
| Phase 3 | NCT01539564 | Apr 2012 → May 2014 | periodontitis | OraPharma | Completed | No outcome recorded |
| Phase 3 | NCT01403662 | Jul 2011 → Feb 2014 | bipolar depression | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT01083420 | Mar 2010 → Mar 2011 | lichen planus, oral | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00662532 | Apr 2008 → Apr 2009 | periodontitis | OraPharma | Completed | No outcome recorded |
| Phase 3 | NCT00392223 | Oct 2007 → Jun 2008 | acne | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00371332 | Jan 2004 → ? | periodontitis | OraPharma | Completed | No outcome recorded |
| Phase 3 | NCT00146809 | Dec 2003 → Dec 2005 | multiple system atrophy | German Parkinson Study Group (GPS) | Completed | No outcome recorded |
| Phase 3 | NCT00733057 | Aug 2003 → Mar 2007 | — | Shalvata Mental Health Center | Completed | No outcome recorded |
| Phase 3 | NCT00047723 | Jan 2003 → Jan 2007 | amyotrophic lateral sclerosis | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 3 | NCT00154895 | Jun 2001 → Mar 2005 | pneumothorax | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00203697 | — | idiopathic pulmonary fibrosis | University of California, Los Angeles | Unknown | No outcome recorded |
| Phase 439 trials | ||||||
| Phase 4 | NCT06699966 | Jun 2027 → Jun 2031 expected | major depressive disorder | Stony Brook University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07068607 | Apr → Oct 2025 overdue | Helicobacter pylori infectious disease, dyspepsia, gastric cancer, gastritis +1 | Yongquan Shi | Recruiting | No outcome recorded |
| Phase 4 | NCT06246396 | Jan 2025 → Jul 2028 expected | resistant hypertension | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT06523764 | Nov 2024 → Aug 2025 overdue | chronic gastritis | Xijing Hospital of Digestive Diseases | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06561711 | Aug 2024 → Feb 2026 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT06561698 | Aug 2024 → Aug 2026 overdue | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT06603688 | Nov 2023 → Nov 2024 | Helicobacter pylori infectious disease, chronic gastritis | Xijing Hospital of Digestive Diseases | Unknown | No outcome recorded |
| Phase 4 | NCT06307288 | Oct 2023 → Jun 2024 | rosacea | Second Affiliated Hospital of Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 4 | NCT05512910 | Mar 2023 → Mar 2025 overdue | basilar artery occlusion, ischemic stroke | Xijing Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05586815 | Jan 2023 → Jan 2024 | Acinetobacter infectious disease | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT05575427 | Nov 2022 → Jul 2024 | nosocomial infection | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT05487417 | Nov 2022 → Jun 2025 overdue | ischemic stroke | Xijing Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06818578 | Sep 2022 → Aug 2024 | dental pulp necrosis, pulpitis, teeth present at birth | Inonu University | Completed | No outcome recorded |
| Phase 4 | NCT06044090 | Sep 2022 → Dec 2023 | — | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT04558502 | Jan → Jun 2022 | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT04940767 | Jun 2021 → Apr 2023 | acne | Edward Lain, MD | Completed | No outcome recorded |
| Phase 4 | NCT04531059 | Oct 2020 → Dec 2022 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03762915 | May 2019 → Apr 2022 | — | University of Minnesota | Completed | No outcome recorded |
| Phase 4 | NCT04076098 | Jun 2018 → Dec 2020 | periodontitis | Mahsa University | Completed | No outcome recorded |
| Phase 4 | NCT03369951 | Mar 2018 → Jul 2019 | bacterial infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT03340350 | May 2017 → Jun 2018 | post-traumatic stress disorder | Sriram Ramaswamy | Completed | No outcome recorded |
| Phase 4 | NCT02968602 | Mar 2017 → Jul 2019 | nicotine dependence, schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT04036890 | Jun 2016 → Oct 2019 | periodontitis | National Dental Centre, Singapore | Completed | No outcome recorded |
| Phase 4 | NCT02712775 | Mar 2016 | liver disorder | Medical University of South Carolina | Withdrawn | No outcome recorded |
| Phase 4 | NCT02695446 | Mar → Apr 2016 | acne | BioPharmX, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02124811 | Feb 2015 → Nov 2016 | schizoaffective disorder, schizophrenia | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02263872 | Oct 2014 → Jun 2016 | major depressive disorder | Pakistan Institute of Living and Learning | Completed | No outcome recorded |
| Phase 4 | NCT02618317 | Jul 2013 → Feb 2016 | chronic kidney disease | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT02355977 | Jun 2013 → Sep 2014 | chronic periodontitis | Zhejiang University | Completed | No outcome recorded |
| Phase 4 | NCT01647282 | Oct 2012 → Dec 2015 | chronic periodontitis | University of Nebraska | Completed | No outcome recorded |
| Phase 4 | NCT01514422 | May 2011 → Aug 2013 | bipolar depression | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT01206348 | Sep 2010 → Jul 2011 | acne | Medicis Global Service Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01133080 | Jun 2010 → Jan 2013 | schizophrenia | Shalvata Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT05014906 | May 2010 → Sep 2011 | rosacea | Dermatology Specialists Research | Completed | No outcome recorded |
| Phase 4 | NCT00988026 | Jun 2009 → Feb 2010 | adult acne | Darier | Unknown | No outcome recorded |
| Phase 4 | NCT00668746 | Dec 2007 → Feb 2009 | periodontitis | OraPharma | Completed | No outcome recorded |
| Phase 4 | NCT00409747 | Nov 2006 → Jun 2010 | autism | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00294502 | Sep 2003 → May 2004 | end stage renal failure | Henry Ford Health System | Completed | No outcome recorded |
| Phase 4 | NCT00145106 | Mar → Aug 2002 | acne | KGL, Inc. | Completed | No outcome recorded |
| Phase not applicable24 trials | ||||||
| — | NCT07239739 | Jun → Nov 2026 expected | periapical periodontitis | Faiz ur rahman | Not yet recruiting | No outcome recorded |
| — | NCT07305896 | Dec 2025 → Dec 2028 expected | intracerebral hemorrhage | The First Hospital of Jilin University | Not yet recruiting | No outcome recorded |
| — | NCT06537921 | Oct 2024 → Sep 2027 expected | major depressive disorder, obesity disorder | King's College London | Recruiting | No outcome recorded |
| — | NCT06004401 | Aug 2023 → Aug 2025 | — | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| — | NCT05902819 | May 2023 → Mar 2026 | post-traumatic stress disorder, substance-related disorder | Psychiatric University Hospital, Zurich | Completed | No outcome recorded |
| — | NCT05958069 | Mar 2023 → Mar 2024 | epilepsy | Xijing Hospital | Unknown | No outcome recorded |
| — | NCT06027151 | Oct 2022 → Jul 2023 | diabetes mellitus, periodontitis | Riphah International University | Completed | No outcome recorded |
| — | NCT04923113 | Jun 2021 → Jan 2022 | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| — | NCT04433143 | May 2020 → May 2021 | acne | Gang Wang | Unknown | No outcome recorded |
| — | NCT04125706 | Nov 2019 → Jul 2020 | periodontitis | Riyadh Elm University | Unknown | No outcome recorded |
| — | NCT03768557 | Apr 2017 → Oct 2018 | — | University of Oxford | Completed | No outcome recorded |
| — | NCT02765100 | Oct 2014 → Oct 2019 | bipolar disorder, depressive disorder, obesity disorder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| — | NCT01531582 | Apr 2012 → Dec 2014 | Angelman syndrome | University of South Florida | Completed | No outcome recorded |
| — | NCT01659320 | Mar 2012 → Apr 2015 | depressive disorder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| — | NCT01561742 | Feb 2012 → Jan 2015 | schizophrenia | The University of Texas Health Science Center, Houston | Unknown | No outcome recorded |
| — | NCT01600625 | Nov 2011 → Jul 2012 | eye adnexa disorder | Yonsei University | Completed | No outcome recorded |
| — | NCT01317550 | Jul 2011 → Feb 2016 | lung cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT01053156 | Jan 2010 → Dec 2011 | fragile X syndrome | University of California, Davis | Completed | No outcome recorded |
| — | NCT00836355 | Apr → Dec 2009 | ischemic stroke | NYU Langone Health | Terminated | No outcome recorded |
| — | NCT01779089 | Feb 2009 → Mar 2016 | diabetic kidney disease | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Unknown | No outcome recorded |
| — | NCT00858689 | Oct 2007 → Nov 2008 | fragile X syndrome | FRAXA Research Foundation | Completed | No outcome recorded |
| — | NCT00355459 | Aug 2005 → Apr 2007 | dry eye syndrome | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| — | NCT00777413 | Nov 2002 | — | Ranbaxy Laboratories Limited | Completed | No outcome recorded |
| — | NCT00378781 | — | cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 65 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT04210713 Comparator | Feb 2020 → Sep 2023 | alcohol dependence, cognitive disorder, mental disorder | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 1 | NCT02947763 Comparator | Nov 2016 → Jan 2018 | periapical periodontitis | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT02193269 Comparator | Jul 2013 → Nov 2015 | cognitive impairment with or without cerebellar ataxia | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT00243893 Comparator | Jul 2004 → Oct 2008 | arteriovenous malformations of the brain, brain aneurysm | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT06889701 Background | Apr 2025 → Aug 2026 overdue | periprosthetic joint infection | TenNor Therapeutics Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02133885 Comparator | Jan 2023 → Mar 2024 | hypertensive disorder | University of Florida | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04594733 Comparator | Dec 2021 → Aug 2022 | fibromyalgia | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1/2 | NCT03244592 Comparator | Jan → Mar 2018 | alcohol-related disorders, cognitive disorder | University of California, Los Angeles | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02060149 Background | Mar 2014 → Mar 2015 | pneumonia | Xijing Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT00855062 Comparator | Apr 2008 → Dec 2009 | HIV infectious disease, cognitive impairment with or without cerebellar ataxia | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 1/2 | NCT00916461 Comparator | May 2006 → Mar 2008 | schizophrenia | Stanley Medical Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT01048983 Comparator | — | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT05826912 Comparator | Aug 2024 → Aug 2028 expected | traumatic brain injury | University of California, San Francisco | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06201793 Comparator | Jan 2024 → Jan 2025 | inflammatory bowel disease | Mostafa Bahaa | Completed | No outcome recorded |
| Phase 2 | NCT04202263 Comparator | Sep 2019 → Sep 2023 | allergic rhinitis, asthma | State University of New York - Downstate Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT04104685 Comparator | Sep 2019 → Feb 2020 | acne | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03888378 Comparator | Apr 2019 → Sep 2020 | eye adnexa disorder | Hovione Scientia Limited | Completed | No outcome recorded |
| Phase 2 | NCT03964935 Comparator | Dec 2018 → Aug 2019 | periodontal disorder | University of Baghdad | Unknown | No outcome recorded |
| Phase 2 | NCT03263273 Comparator | Oct 2017 → Mar 2019 | rosacea | Hovione Scientia Limited | Completed | No outcome recorded |
| Phase 2 | NCT02569307 Comparator | Oct 2015 → Dec 2018 | psychotic disorder | Pakistan Institute of Living and Learning | Completed | No outcome recorded |
| Phase 2 | NCT01463384 Comparator | Sep 2011 → Oct 2012 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Huntington Medical Research Institutes | Completed | No outcome recorded |
| Phase 2 | NCT01297816 Comparator | Dec 2010 | retinal detachment | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01073813 Comparator | Feb 2010 → Dec 2011 | multiple sclerosis, optic neuritis | University of Calgary | Terminated | No outcome recorded |
| Phase 2 | NCT00401921 Comparator | Oct 2006 → Jun 2010 | carotid stenosis | Brigham and Women's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT00203112 Comparator | Jun 2004 → Jun 2006 | relapsing-remitting multiple sclerosis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06821763 Comparator | May → Oct 2025 overdue | periodontitis, pulpitis | Komal Ashraf Khan | Not yet recruiting | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT05644301 Comparator | Sep 2023 → Sep 2026 expected | major depressive disorder | University of Antwerp | Recruiting | No outcome recorded |
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05836740 Comparator | May 2023 → May 2024 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05074147 Background | May 2022 → Nov 2024 | osteomyelitis | Tourcoing Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT04478500 Comparator | Jul 2020 → Aug 2024 | resistant hypertension | Royal Perth Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03947827 Comparator | Feb 2020 → Jan 2025 | — | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 3 | NCT02541032 Comparator | Dec 2015 → Jun 2019 | periodontal disorder, transient ischemic attack | University of South Carolina | Unknown | No outcome recorded |
| Phase 3 | NCT02907437 Comparator | Jan 2015 → Feb 2017 | schizophrenia | Beer Yaakov - Ness Ziona Mental Health Center | Unknown | No outcome recorded |
| Phase 3 | NCT01931150 Background | Aug 2013 → Sep 2015 | acneiform dermatitis, cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT01429272 Comparator | Sep 2011 → Aug 2015 | bipolar depression | Laureate Institute for Brain Research, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01320982 Comparator | Mar 2011 → Jun 2012 | schizoaffective disorder, schizophrenia | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00666887 Comparator | Jan 2009 → Dec 2014 | multiple sclerosis | Dr. Luanne Metz | Completed | No outcome recorded |
| Phase 3 | NCT03414502 Comparator | Dec 2007 → Mar 2028 expected | rheumatoid arthritis | University of Nebraska | Recruiting | No outcome recorded |
| Phase 3 | NCT00529555 Comparator | Jan 2006 → Dec 2008 | periodontitis, chronic, adult | Sunstar Americas | Completed | No outcome recorded |
| Phase 3 | NCT00579644 Comparator | Mar 2001 → May 2006 | rheumatoid arthritis | University of Nebraska | Completed | No outcome recorded |
| Phase 415 trials | ||||||
| Phase 4 | NCT07405684 Comparator | Feb 2026 → Dec 2027 expected | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07405697 Comparator | Feb 2026 → Dec 2027 expected | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07437209 Comparator | Dec 2024 → Dec 2025 | periodontitis, aggressive | Center for Advanced Rejuvenation and Esthetics | Completed | No outcome recorded |
| Phase 4 | NCT05530252 Comparator | Sep → Dec 2022 | periodontitis | Beijing Stomatological Hospital, Capital Medical University | Completed | No outcome recorded |
| Phase 4 | NCT04020588 Comparator | Feb 2019 → Jun 2020 | schizophrenia | Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT02719392 Comparator | Aug 2017 → Jun 2026 | bipolar depression | Massachusetts General Hospital | Suspended | No outcome recorded |
| Phase 4 | NCT02913118 Background | Jul 2016 → Jan 2019 | — | Qingfeng Pharmaceutical Group | Unknown | No outcome recorded |
| Phase 4 | NCT01809158 Comparator | Apr 2013 → May 2016 | schizophrenia | Addis Ababa University | Completed | No outcome recorded |
| Phase 4 | NCT01869907 Comparator | Sep 2011 → Aug 2014 | radiculopathy | Ziekenhuis Oost-Limburg | Completed | No outcome recorded |
| Phase 4 | NCT01313208 Background | Mar 2011 → Feb 2013 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT01493622 Comparator | Jun 2010 → Nov 2011 | schizophrenia | Central South University | Completed | No outcome recorded |
| Phase 4 | NCT02030912 Comparator | Dec 2009 → Dec 2012 | — | Helperby Therapeutics Ltd | Completed | No outcome recorded |
| Phase 4 | NCT00930020 Comparator | Jul 2009 → Jul 2012 | stroke disorder | Singhealth Foundation | Terminated | No outcome recorded |
| Phase 4 | NCT00765336 Comparator | Nov 2006 → Dec 2008 | — | Medicis Pharmaceutical Corporation | Completed | No outcome recorded |
| Phase 4 | NCT00240513 Comparator | Aug 2004 → Dec 2006 | acne | Derm Research @ 888 Inc. | Terminated | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT03763110 Comparator | Oct 2016 → Dec 2018 | dental pulp necrosis | Cairo University | Unknown | No outcome recorded |
| — | NCT02359006 Comparator | Mar 2015 → Apr 2017 | opiate dependence | Yale University | Completed | No outcome recorded |
| — | NCT01802216 Comparator | Feb 2014 → Sep 2017 | chronic kidney disease, periodontal disorder | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT01433055 Comparator | Jul 2011 → Jan 2014 | schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT03507556 Background | Jun 2010 → Nov 2021 overdue | — | Jordan University of Science and Technology | Active not recruiting | No outcome recorded |
| — | NCT00893724 Comparator | Jun 2009 → Aug 2011 | diabetic macular edema, wet macular degeneration | Mid-Atlantic Retina Consultations, Inc. | Unknown | No outcome recorded |
| — | NCT00556491 Comparator | Dec 2007 → Jul 2011 | acute kidney injury | Tarek M. El-Achkar | Completed | No outcome recorded |
| — | NCT01049438 Background | Aug 2006 → Sep 2009 | methicillin-resistant staphylococcus aureus infectious disease | Natividad Medical Center | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-02-20 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Exclusive Launch of Two Strengths of a Generic Version of Solodyn® in the United States tevapharm.com ↗ |
| 2009-03-18 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval and Launch of Generic Solodyn® Extended-Release Tablets tevapharm.com ↗ |
Evidence & citations 32 cited values
Every value below carries the sentence it was read from. 266 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Minocycline | “Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine...” NCT05894954 ↗254“Based on the susceptibility results and penicillin-allergic test, a tailored 7-day triple or quadruple therapy regimen is prescribed, including Tegoprazan , Amoxicillin,...” NCT07405697 ↗ “The purpose of this research project is to determine the effects of oral tetracycline such as Minocycline (Minocin) on tear film composition and tear lipid (meibomian gland...” NCT00355459 ↗ “Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12,...” NCT02696512 ↗ “The TAP was freshly prepared and proportioned in equal parts by volume (metronidazole, minocycline, and ciprofloxacin=1:1:1) before the scheduled treatment appointment.” NCT04547764 ↗ “mix metronidazole, ciprofloxacin and minocycline in ratio 1:1:1 with normal saline and placed as intra canal medicament during first visit of root canal treatment.” NCT06821763 ↗ “Hoshino et al. recommended a ratio of 1:1:1 of metronidazole (500 mg), minocycline (100 mg) and ciprofloxacin (200 mg) for the 3Mix formulation” NCT03763110 ↗ “ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.” NCT00881907 ↗ “including Tegoprazan , Amoxicillin, Clarithromycin, Levofloxacin, Bismuth Potassium Citrate, Metronidazole, Doxycycline or Minocycline.” NCT07405684 ↗ “AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019” NCT04940767 ↗ “A low-dose modified formulation of minocycline hydrochloride, DFD-29, is under evaluation for treating papulopustular rosacea (PPR).” PMID 40042869 ↗ May 2025 “Intracanal medicament paste composed of Ciprofloxacin, Metronidazole, and Minocycline. Placed in the root canal for several weeks.” NCT07239739 ↗ “Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine” NCT01313208 ↗ “Subjects who elect to continue into this open-label study will receive supplies of active FMX103 1.5% minocycline foam.” NCT03276936 ↗ “Minocycline is associated with a number of adverse reactions for which patients should be carefully monitored.” NCT05367362 ↗ “We assessed the efficacy, safety, and dose response of DFD-29, a minocycline extended-release oral capsule.” PMID 35096250 ↗ Dec 2021 “The study lock solution is made up of minocycline, disodium ethylenediaminetetraacetate, and ethanol.” NCT01539343 ↗ “oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)” NCT01931150 ↗ “ciprofloxacin metronidazole minocycline paste will be :placed in the canal and kept for 4 weeks.” NCT04319575 ↗ “Minocycline is a second-generation tetracycline with pleiotropic neuroprotective properties” NCT07594301 ↗ “minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.” NCT00881491 ↗ “Minocycline is an antibiotic belonging to the group of the Tetracyclines.” NCT00146809 ↗ “PRF with Minocycline evaluated as an adjunct to non-surgical therapy” NCT07437209 ↗ “FMX101 topical foam containing 4% minocycline compared to vehicle” NCT03271021 ↗ “minocycline (Minoz, 100 mg, Ranbaxy, India)” NCT06818578 ↗ “Ciprofloxacin, Metronidazole, & Minocycline” NCT01976065 ↗ “Minocycline is a potent inhibitor of MMP9.” PMID 35349976 ↗ Oct 2021 “BPX-01 Minocycline 1% Topical Gel (BPX-01)” NCT02709096 ↗ “FMX101 4% minocycline foam” NCT04960930 ↗ “3% Minocycline Foam” NCT04104685 ↗ “minocycline” NCT01049438 ↗ “Minocycline” NCT02099240 ↗ |
| Known as | AMZEEQ | “topical minocycline foam (AMZEEQ®)” NCT07462702 ↗ |
| Known as | Arestin | “The aim of this randomised pilot clinical trial was to determine if type 1 diabetes patients with periodontitis will experience a reduction in HbA1c levels when treated with...” PMID 15536785 ↗ Oct 20043“This split-mouth randomized controlled clinical trial (RCT) aims to compare the clinical efficacy of PRF combined with minocycline versus minocycline microspheres hydrochloride...” NCT07437209 ↗ |
| Known as | Arestin (minocycline microspheres) 1 mg | “Arestin (minocycline microspheres) 1 mg” NCT01647282 ↗ |
| Known as | Borymycin | “Minocycline (Borymycin)” NCT00930020 ↗ |
| Known as | BPX-01 | “BPX-01 Minocycline 1% Topical Gel (BPX-01)” NCT02709096 ↗ |
| Known as | BPX-04 | “Drug: BPX-04 1% minocycline topical gel” NCT03050086 ↗1“BPX-04 minocycline topical gel” NCT03667222 ↗ |
| Known as | DFD-29 | “Treatment-A: A single 40 mg dose of DFD-29 (Minocycline Hydrochloride) (1 × 40 mg Extended-Release capsule) administered following a 10-hour overnight fast” NCT05452785 ↗1“We assessed the efficacy, safety, and dose response of DFD-29, a minocycline extended-release oral capsule.” PMID 35096250 ↗ Dec 2021 |
| Known as | doxycycline | “Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).” NCT02060149 ↗ |
| Known as | Dynacin | “Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules.” NCT01433055 ↗ |
| Known as | FMX-101 | “This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of...” NCT02815280 ↗3“daily dose of topical FMX-101 minocycline (4%) foam for sixteen consecutive days” NCT02250859 ↗ “FMX-101, 4% minocycline foam applied topically once daily for 12 weeks” NCT02815267 ↗ “FMX101 4% minocycline foam” NCT04960930 ↗ |
| Known as | FMX103 | “Subjects who elect to continue into this open-label study will receive supplies of active FMX103 1.5% minocycline foam.” NCT03276936 ↗ |
| Known as | FXFM244 | “This is a pilot phase II study to evaluate the tolerability and safety and to monitor the clinical efficacy of Topical Minocycline Foam FXFM244 in moderate to severe Rosacea patients.” NCT01134991 ↗1“Topical Minocycline Foam FXFM244” NCT07462702 ↗ |
| Known as | MINO | “whether minocycline (MINO), an FDA-approved antibiotic medication, affects any of the above listed measures” NCT04210713 ↗ |
| Known as | Minocin | “The purpose of this research project is to determine the effects of oral tetracycline such as Minocycline (Minocin) on tear film composition and tear lipid (meibomian gland...” NCT00355459 ↗1“Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment” NCT01600625 ↗ |
| Known as | Minocyclin | “* Minocyclin : 100mg/8h to 12h” NCT05074147 ↗ |
| Known as | Minocycline (generic name) | “Minocycline (generic name)” NCT02178813 ↗ |
| Known as | minocycline extended release | “Drug: minocycline extended release” NCT00765336 ↗ |
| Known as | Minocycline Extended-Release Tablets | “The study will include Minocycline Extended-Release Tablets, a new once-daily formulation of minocycline, compared with a placebo or inactive pill.” NCT00765336 ↗ |
| Known as | minocycline HCl | “DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.” NCT03340961 ↗5“Minocycline HCl 2.1% gel as an adjunct to scaling and root planing.” NCT00529555 ↗ “Minocycline HCl Microspheres, 1mg minocycline powder per cartridge.” NCT03964935 ↗ “1 mg/kg extended release minocycline HCL, once daily for 84 days.” NCT00765336 ↗ “locally-applied minocycline HCl (1 mg)” NCT01647282 ↗ |
| Known as | Minocycline HCL Extended-Release Tablets | “Solodyn (Minocycline HCL Extended-Release Tablets)” NCT01206348 ↗ |
| Known as | minocycline hydrochloride | “The experimental group will receive an initial dose of 200 mg of minocycline hydrochloride capsules in addition to medical therapy after randomization, followed by 100 mg...” NCT07305896 ↗10“Minocycline hydrochloride capsules: 100 mg/capsule. Administered orally q12h ± 1h daily, doubling the first dose, 200 mg (2 capsules) orally, then 100 mg (1 capsule) each time...” NCT06889701 ↗ “The treatment group will receive 200 mg intravenous/oral minocycline hydrochloride in addition to endovascular thrombectomy for a total of 21 days.” NCT05367362 ↗ “Minocycline hydrochloride capsules, 40 mg will be administered orally once daily for 16 weeks.” NCT05597462 ↗ “50 mg per capsule, containing 50mg of Minocycline Hydrochloride” NCT07338175 ↗ “2% minocycline hydrochloride controlled-delivery system (MHS)” NCT04036890 ↗ |
| Known as | Minocycline hydrochloride (HCL) | “Clinical parameters bleeding on probing (BOP), pocket depth (PD), and clinical attachment level (CAL) have been improved when Minocycline hydrochloride (HCL) microspheres was...” NCT03964935 ↗ |
| Known as | minocycline microspheres hydrochloride | “This split-mouth randomized controlled clinical trial (RCT) aims to compare the clinical efficacy of PRF combined with minocycline versus minocycline microspheres hydrochloride...” NCT07437209 ↗ |
| Known as | Minoz | “minocycline (Minoz, 100 mg, Ranbaxy, India)” NCT06818578 ↗ |
| Known as | Mirocin | “In the minocycline group, 20 mL of 2% lidocaine hydrochloride (400mg) followed by a solution of 20 mL of normal saline containing 300 or 400 mg (7mg/kg) of minocycline...” NCT00154895 ↗ |
| Known as | Periocline | “active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan)” NCT04036890 ↗ |
| Known as | Solodyn | “Solodyn (Minocycline HCL Extended-Release Tablets)” NCT01206348 ↗1“Solodyn (Minocycline) Fasting” NCT05452785 ↗ |
| Action | Inhibit | “inhibits caspase-1 and caspase-3 expression” NCT00029874 ↗ |
| Modality | Small molecule | “Minocycline-a medication currently approved by the FDA for treatment of bacterial infections-is a tetracycline antibiotic with high central nervous system penetration when taken orally.” NCT00047723 ↗ |
| Route | Oral | “when taken orally” NCT00047723 ↗ |
| Target | MMP9 | “it lowers matrix metalloproteinase 9 (MMP9) levels” NCT01053156 ↗ |